Choriogonadotropin alfa - Biologic Drug Details

Summary for choriogonadotropin alfa

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for choriogonadotropin alfa

Recent Clinical Trials for choriogonadotropin alfa

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Ferring Pharmaceuticals	PHASE1
Sports Medicine Research and Testing Laboratory	Early Phase 1
Sheba Medical Center	Phase 4

See all choriogonadotropin alfa clinical trials

Pharmacology for choriogonadotropin alfa

Established Pharmacologic Class	Gonadotropin
Chemical Structure	Gonadotropins

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for choriogonadotropin alfa Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for choriogonadotropin alfa Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for choriogonadotropin alfa Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for Choriogonadotropin Alfa

Last updated: February 16, 2026

Overview

Choriogonadotropin alfa (brand name Ovitrelle, Pregnyl), a recombinant form of human chorionic gonadotropin (hCG), is used in infertility treatments, primarily to induce ovulation and support early pregnancy. The drug’s market is influenced by regulatory approvals, competition, technological advances, and shifting healthcare policies.

Market Size and Growth

The global market for gonadotropins, including choriogonadotropin alfa, was valued at approximately $1.2 billion in 2022. Expected CAGR (Compound Annual Growth Rate) from 2023 to 2028 is roughly 7-8%, driven by rising infertility prevalence and geographic expansion into emerging markets.

North America holds the largest share, accounting for over 40% of sales in 2022. Europe follows, with steady growth due to aging populations and increased awareness of infertility treatments. Asia-Pacific exhibits the fastest growth rate—projected at 10% CAGR—due to expanding healthcare infrastructure and rising healthcare expenditure.

Market Drivers

• Infertility Trends: Rising age at first childbirth, lifestyle factors, and environmental influences increase demand for assisted reproductive technologies (ART).
• Technological Advancements: Improved ovulation induction protocols and recombinant hormone formulations enhance efficacy and safety profiles, making choriogonadotropin alfa preferable over extraction-based alternatives.
• Regulatory Approvals: More countries approve recombinant formulations, expanding access.
• Insurance Coverage and Reimbursement: Policies that cover ART procedures boost sales, especially in developed economies.

Competitive Landscape

The market features multiple competitors, including Ferring Pharmaceuticals (as the primary producer of recombinant choriogonadotropin alfa), Merck, and Sun Pharmaceutical Industries, which manufacture biosimilars and alternative gonadotropin products.

Company	Market Share (2022)	Key Products	Notable Developments
Ferring Pharmaceuticals	~70%	Ovitrelle	Patent protection until 2030; biosimilar launches expected post-2025
Merck KGaA (EMD Serono)	~15%	Pregnyl (urinary-derived), biosimilars	Expanding biosimilar presence
Sun Pharmaceutical Industries	~10%	GnRH analogs, biosimilars	Focus on emerging markets

Patent expirations are critical; Ferring’s patent for Ovitrelle extends until 2030, delaying biosimilar penetration but opening opportunities thereafter.

Regulatory and Policy Impact

• FDA and EMA: Approve recombinant formulations with strict biosimilar pathways. Biosimilar approvals are expected to intensify post-2025.
• Insurance Policies: Reimbursements favor recombinant products over urinary-derived ones due to safety and consistency.

Financial Trajectory

• Revenue Projections: For 2023, revenues are estimated at $900 million globally, with growth anticipated to reach $1.5 billion by 2028, assuming consistent market expansion.
• Pricing Trends: Recombinant formulations maintain premium pricing over urinary-based products, though biosimilars are expected to reduce prices by 20-30% post-2025.
• Investment in R&D: Market players invest in biosimilar development, with R&D spending around 10% of sales, aiming to reduce costs and improve biosimilar efficacy.

Risks and Challenges

• Patent Litigation: Challenges to patent exclusivity could accelerate biosimilar entry.
• Market Penetration of Biosimilars: Post-2025, biosimilar products may undercut branded formulations on price.
• Regulatory Delays: Variability in approval timelines across regions can slow market expansion.
• Supply Chain Disruptions: Manufacturing complexities of biologics create vulnerability to supply disruptions, affecting revenues.

Summary

Choriogonadotropin alfa operates in a stable yet evolving market driven by demographic trends, technological advancements, and regulatory developments. Revenue growth depends heavily on patent protections, biosimilar entry, and pricing strategies. The market will face increasing competition post-2025, with biosimilars poised to capture market share.

---

Key Takeaways

• The global market for gonadotropins was ~$1.2 billion in 2022, expected to grow at 7-8% annually through 2028.
• Ferring holds approximately 70% market share; biosimilar entrants are anticipated post-2025.
• Revenue projections indicate growth from ~$900 million in 2023 to ~$1.5 billion in 2028.
• Patent extensions until 2030 delay biosimilar competition; market entry pressures will increase afterward.
• Pricing strategies and regulatory environments will significantly influence revenue trajectories.

---

FAQs

1. What factors most significantly impact the growth of choriogonadotropin alfa?
Infertility trends, technological improvements, regulatory approvals, and reimbursement policies each influence market expansion.

2. How do biosimilars affect the market for choriogonadotropin alfa?
Biosimilars lower prices and increase competition; their launch post-2025 is expected to reduce revenue margins and market share of original products.

3. When will biosimilar versions of choriogonadotropin alfa likely enter the market?
Biosimilar approvals are expected after patent expiry around 2030, with market entry possibly beginning 1-2 years thereafter.

4. What are the primary risks to revenue growth?
Patent challenges, biosimilar competition, regulatory delays, and supply chain issues.

5. How does geographic distribution influence market dynamics?
North America and Europe dominate revenue; Asia-Pacific’s fast growth offers significant long-term potential.

---

References

[1] Grand View Research, "Gonadotropins Market Size & Trends," 2022.
[2] Evaluate Pharma, "Biologic & Biosimilar Market Outlook," 2023.
[3] U.S. FDA, "Biosimilar Policy and Pathways," 2022.
[4] Ferring Pharmaceuticals Annual Report, 2022.
[5] Pfizer, "Infertility and Reproductive Health Portfolio," 2023.